Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191991 | 0.91 | RET (0.42) | DHODHPTGS2ITKJAK1TYK2 | |
| SCHEMBL13945167 | 0.90 | PIM1 (0.49) | DHODHPTGS2ITKJAK1TYK2 | |
| SCHEMBL4196002 | 0.89 | AURKA (0.47) | PTGS2ITKNTRK1PLK4FGFR2 | |
| SCHEMBL13945054 | 0.89 | ITK (0.44) | PTGS2ITKNTRK1PLK4FGFR2 | |
| SCHEMBL13945160 | 0.88 | AURKA (0.48) | ITKNTRK1PLK4FGFR2FGFR3 | |
| SCHEMBL4197055 | 0.87 | PLK4 (0.45) | PTGS2ITKNTRK1PLK4FGFR2 | |
| SCHEMBL4196328 | 0.87 | ITK (0.53) | ITKPLK4PAK4 | |
| SCHEMBL13945040 | 0.87 | ITK (0.55) | ITKPLK4PAK4 | |
| SCHEMBL4197962 | 0.85 | AURKA (0.46) | ITKNTRK1PLK4FGFR2FGFR3 | |
| SCHEMBL13945144 | 0.85 | IGF1R (0.41) | PTGS2ITKJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008154026-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | DHODH 2460/4885PTGS2 3605/4885KCNH2 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.